Mark Heinen - 24 Jun 2022 Form 4 Insider Report for Better Therapeutics, Inc.

Role: Head of Finance and interim Chief Financial Officer
Signature: /s/ Mark Heinen
Issuer symbol: BTTX on OTC
Transactions as of: 24 Jun 2022
Net transactions value: +$4,000
Form type: 4
Filing time: 28 Jun 2022, 16:24:56 UTC
Previous filing: 10 Jun 2022
Next filing: 14 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTTX	Common Stock	Purchase	$4,000	+2,281		$1.75	2,281	24 Jun 2022	By daughter	F1
holding	BTTX	Common Stock						20,000	24 Jun 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7539 to $1.7576, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7539 to $1.7576, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

Head of Finance and interim Chief Financial Officer